Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81


Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis.

Tseng OL, Spinelli JJ, Gotay CC, Ho WY, McBride ML, Dawes MG.

Ther Adv Musculoskelet Dis. 2018 Apr;10(4):71-90. doi: 10.1177/1759720X18759291. Epub 2018 Mar 22. Review.


Association between Post-Cancer Diagnosis Dietary Inflammatory Potential and Mortality among Invasive Breast Cancer Survivors in the Women's Health Initiative.

Zheng J, Tabung FK, Zhang J, Liese AD, Shivappa N, Ockene JK, Caan B, Kroenke CH, Hébert JR, Steck SE.

Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):454-463. doi: 10.1158/1055-9965.EPI-17-0569. Epub 2018 Jan 22.


A nation-wide multicenter 10-year (1999-2008) retrospective study of chemotherapy in Chinese breast cancer patients.

Li Q, Yang Z, Fan J, He J, Zhang B, Yang H, Xie X, Tang Z, Li H, Qiao Y, Zhang P.

Oncotarget. 2017 Mar 22;8(44):75864-75873. doi: 10.18632/oncotarget.16439. eCollection 2017 Sep 29.


Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients.

Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Tomiguchi M, Sueta A, Murakami K, Omoto Y, Iwase H.

Oncotarget. 2017 Jun 14;8(32):52142-52155. doi: 10.18632/oncotarget.18479. eCollection 2017 Aug 8.


Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods.

Häberle L, Hein A, Rübner M, Schneider M, Ekici AB, Gass P, Hartmann A, Schulz-Wendtland R, Beckmann MW, Lo WY, Schroth W, Brauch H, Fasching PA, Wunderle M.

Geburtshilfe Frauenheilkd. 2017 Jun;77(6):667-678. doi: 10.1055/s-0043-111602. Epub 2017 Jun 28.


Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial.

Bear HD, Wan W, Robidoux A, Rubin P, Limentani S, White RL Jr, Granfortuna J, Hopkins JO, Oldham D, Rodriguez A, Sing AP.

J Surg Oncol. 2017 Jun;115(8):917-923. doi: 10.1002/jso.24610. Epub 2017 Apr 13.


Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.

Gaß P, Fasching PA, Fehm T, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Wuerstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Fersis N, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesselt T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauss T, Thomssen C, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Jacob A, Schmidt K, Belleville E, Hadji P, Brucker SY, Beckmann MW, Wallwiener D, Kümmel S, Löhberg CR.

Breast Care (Basel). 2016 Oct;11(5):315-322. Epub 2016 Oct 27.


Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.

Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Inao T, Sueta A, Fujiwara S, Omoto Y, Iwase H.

Oncotarget. 2016 May 31;7(22):32504-18. doi: 10.18632/oncotarget.8839.


21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.

Jasem J, Amini A, Rabinovitch R, Borges VF, Elias A, Fisher CM, Kabos P.

J Clin Oncol. 2016 Jun 10;34(17):1995-2002. doi: 10.1200/JCO.2015.65.0887. Epub 2016 Mar 21.


Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer.

Tomiguchi M, Yamamoto Y, Yamamoto-Ibusuki M, Goto-Yamaguchi L, Fujiki Y, Fujiwara S, Sueta A, Hayashi M, Takeshita T, Inao T, Iwase H.

Cancer Sci. 2016 Apr;107(4):491-8. doi: 10.1111/cas.12897. Epub 2016 Mar 28.


Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.

Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Inao T, Sueta A, Fujiwara S, Omoto Y, Iwase H.

Cancer Sci. 2015 Nov;106(11):1582-9. doi: 10.1111/cas.12813. Epub 2015 Oct 30.


Host genotype and tumor phenotype of chemokine decoy receptors integrally affect breast cancer relapse.

Yu KD, Wang X, Yang C, Zeng XH, Shao ZM.

Oncotarget. 2015 Sep 22;6(28):26519-27. doi: 10.18632/oncotarget.4470.


Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years.

Potosky AL, O'Neill SC, Isaacs C, Tsai HT, Chao C, Liu C, Ekezue BF, Selvam N, Kessler LG, Zhou Y, Schwartz MD.

Cancer. 2015 Nov 15;121(22):4062-70. doi: 10.1002/cncr.29621. Epub 2015 Aug 20.


Application status of tamoxifen in endocrine therapy for early breast cancer.

Hu Q, Luo T, Zhong X, He P, Tian T, Zheng H.

Exp Ther Med. 2015 Jun;9(6):2207-2212. Epub 2015 Apr 20.


Breast cancer in 30-year-old or younger patients: clinicopathologic characteristics and prognosis.

Yao Y, Cao M, Fang H, Xie J.

World J Surg Oncol. 2015 Feb 12;13:38. doi: 10.1186/s12957-015-0462-4.


Inhibitory and apoptosis-inducing effects of Newcastle disease virus strain AF2240 on mammary carcinoma cell line.

Ahmad U, Ahmed I, Keong YY, Abd Manan N, Othman F.

Biomed Res Int. 2015;2015:127828. doi: 10.1155/2015/127828. Epub 2015 Mar 2.


Clinical significance of pAkt and pErk1/2 expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy.

Liu W, Zhang L, Shi J, Liu Y, Zhou L, Hou K, Qu X, Teng Y.

Oncol Lett. 2015 Apr;9(4):1707-1714. Epub 2015 Feb 16.


C6ORF97-ESR1 breast cancer susceptibility locus: influence on progression and survival in breast cancer patients.

Yamamoto-Ibusuki M, Yamamoto Y, Fujiwara S, Sueta A, Yamamoto S, Hayashi M, Tomiguchi M, Takeshita T, Iwase H.

Eur J Hum Genet. 2015 Jul;23(7):949-56. doi: 10.1038/ejhg.2014.219. Epub 2014 Nov 5.

Supplemental Content

Support Center